A randomized, double-blind, pilot study depicted that compared to topiramate, tiapride is a safe, efficient and well-tolerated prophylactic intervention for people diagnosed with chronic migraine.  Researchers sought to assess safety and effectiveness of tiapride vs. topiramate for chronic migraine prophylaxis. Overall, 56 people (18-65 years of age) suffering from chronic migraine were recruited and segregated into two intervention groups. For 12 weeks, patients in group 1 were given 100 mg tiapride two times a day and patients in group 2 received 25 mg topiramate two times a day.

Alteration in the monthly average number of migraine days was the major outcome ascertained. Measurements were carried out to explore alteration in headache effect as estimated by Headache Impact Test-6, alteration in monthly number of headache days, and percentage of patients with more than 50% and 75% reduction in their monthly migraine days. Overall, 39 subjects (tiapride = 21; topiramate = 18) were incorporated in the intention-to-treat population.

Out of 39, 35 subjects (tiapride = 18; topiramate = 16) finished the study. A mean reduction of migraine days per month in the tiapride group and topiramate group is shown in Table 1:

Regarding other effectiveness variables measured, no inter-group differences were noted. Mild adverse effects were witnessed in both groups. Hence, tiapride was associated with promising prophylactic effects in individuals with chronic migraine when compared to topiramate.